Coronary Stents Market Size to Hit USD 14.20 Billion by 2033

Coronary Stents Market Size, Share, Growth, Segmental Analysis, By Product Type (Drug-Eluting Stents — Cobalt-Chromium DES, Stainless Steel DES, Platinum-Chromium DES, Others; Bare-Metal Stents — Cobalt-Chromium BMS, Stainless Steel BMS; Bioresorbable Vascular Scaffolds; Others), By Material (Cobalt-Chromium, Stainless Steel, Platinum-Chromium, Nitinol, Others), By End User (Hospitals, Ambulatory Surgical Centers, Cardiac Catheterization Laboratories, Others), By Application (Acute Myocardial Infarction, Stable Angina, Unstable Angina, Others), By Region (North America — U.S., Canada; Europe — Germany, UK, France, Italy, Spain, Rest of Europe; Asia Pacific — China, Japan, India, South Korea, Rest of Asia Pacific; Latin America — Brazil, Mexico, Rest of Latin America; Middle East & Africa — GCC, South Africa, Rest of Middle East & Africa), and Market Forecast, 2026 – 2033

  • Published: Apr, 2026
  • Report ID: 410
  • Pages: 160+
  • Format: PDF / Excel.

This report contains the Latest Market Figures, Statistics, and Data.

Get a Sample
logo

Coronary Stents Market Size to Hit USD 14.20 Billion by 2033

(An Updated Version is Available)

1. Preface

  • 1.1 Report Description and Scope

  • 1.2 Research Objectives

  • 1.3 Key Assumptions and Limitations

  • 1.4 Target Audience

2. Executive Summary

  • 2.1 Market Overview and Snapshot

  • 2.2 Key Market Findings and Highlights

  • 2.3 Market Size Estimation and Forecast Summary

  • 2.4 Key Trends at a Glance

  • 2.5 Recommendations for Market Participants

3. Research Methodology

  • 3.1 Research Design and Approach

  • 3.2 Primary Research (Interventional Cardiologists, Vascular Surgeons, Cath Lab Directors, Hospital Procurement Managers, Medical Device Regulatory Affairs Specialists, KOL Interactions)

  • 3.3 Secondary Research (Annual Reports, FDA 510(k)/PMA Device Databases, EMA Cardiovascular Device Regulatory Data, WHO Global Health Observatory CVD Statistics, ACC/AHA/ESC PCI Guidelines, Journal of the American College of Cardiology (JACC), Circulation Cardiovascular Interventions, ClinicalTrials.gov, NPPA India Coronary Stent Price Notifications, PMDA Japan Device Approvals)

  • 3.4 Top-Down and Bottom-Up Estimation Approach

  • 3.5 Data Triangulation and Validation

  • 3.6 Market Forecast Assumptions and Key Parameters

4. Market Overview

  • 4.1 Introduction to Coronary Stents and Their Role in Percutaneous Coronary Intervention (PCI) for Coronary Artery Disease Management

  • 4.2 Historical Market Background and Evolution (Bare-Metal Stents → First-Generation DES → Second-Generation DES with Biodegradable Polymers → Bioresorbable Vascular Scaffolds → Polymer-Free DES → AI-Assisted Robotic PCI Delivery)

  • 4.3 Market Scope and Definition

  • 4.4 Parent Market and Adjacent Market Analysis (Interventional Cardiology Devices, Vascular Stents, Drug-Coated Balloons, Mechanical Circulatory Support, Coronary Imaging — IVUS/OCT)

  • 4.5 Regulatory Overview

    • 4.5.1 U.S. FDA — 510(k) Clearance and PMA Approval for Coronary Stents (FDA Robotic PCI System Approval June 2025; Boston Scientific Synergy XD Bioabsorbable Polymer DES Approval February 2025)

    • 4.5.2 EU MDR 2017/745 — Class III Active Implantable Device Compliance; EMA Updated Cardiovascular Device Regulations for Bioresorbable Stents (April 2025)

    • 4.5.3 Medtronic Resolute Onyx CE Clearance with Updated Polymer for Faster Endothelial Healing (January 2025)

    • 4.5.4 India NPPA Coronary Stent Price Notification — NLEM Price Cap Revision (July 2024 and March 2025 ~2% Inflation Adjustment: BMS ₹10,692.69, DES ₹38,933.14)

    • 4.5.5 Japan PMDA Biosensors BioFreedom Ultra Approval (May 2022); PMDA Premium Tier Reimbursement for Resorbable Stents Linked to Clinical Performance

    • 4.5.6 China NMPA Coronary Stent Registration Requirements and Centralized Volume-Based Procurement (VBP) Policy

    • 4.5.7 ISO 10993 Biocompatibility and ISO 14630 Non-Active Surgical Implant Standards for Coronary Stents

  • 4.6 Technology and Innovation Timeline

    • 4.6.1 Generation 1: Bare-Metal Stents (BMS) — Stainless Steel Platform (1986 Puel/Sigwart)

    • 4.6.2 Generation 2: First-Generation Drug-Eluting Stents — Durable Polymer + Sirolimus/Paclitaxel (Cypher, TAXUS)

    • 4.6.3 Generation 3: Second-Generation DES — Thinner Struts, Biocompatible/Biodegradable Polymers + Everolimus/Zotarolimus (XIENCE, Resolute Onyx, Synergy)

    • 4.6.4 Generation 4: Polymer-Free DES — BioFreedom Biolimus A9 Coating Without Permanent Polymer (PMDA/FDA Approved)

    • 4.6.5 Generation 5: Bioresorbable Vascular Scaffolds (BVS/BRS) — Fully Absorbable Scaffolds (ABSORB BVS, Magmaris Magnesium, DynamX Bioadaptor — TCT 2024 Data)

    • 4.6.6 Emerging: Dual-Therapy Stents (OrbusNeich Genous/Combo EPC Capture + Drug Elution), 4D-Printed Personalized Stent Architectures, AI-Guided Robotic PCI Delivery Systems

  • 4.7 Coronary Stent Types Comparison: BMS vs. DES vs. Bioresorbable Scaffolds — Clinical Outcomes, DAPT Duration, Restenosis Rates, Long-Term Safety, and Reimbursement Status

  • 4.8 Drug-Coated Balloon (DCB) as Adjacent Competitive Therapy — Agent Paclitaxel DCB FDA Approval (AGENT IDE Trial: 38% Risk Reduction in Target Lesion Failure, March 2024)

5. Market Dynamics

  • 5.1 Market Drivers

    • 5.1.1 Rising Global Prevalence of Coronary Artery Disease (CAD) — WHO Reports Cardiovascular Disease as Leading Cause of Global Death (17.9 Million Annually); CAD Remains No. 1 Cause of Death in the U.S. (Clinical Trials Arena, February 2022)

    • 5.1.2 Rapidly Aging Global Population Driving Exponential Increase in CAD Risk — Over-60 Age Group Disproportionately Susceptible to Atherosclerosis and Acute MI Requiring PCI

    • 5.1.3 Growing Adoption of Minimally Invasive PCI Over Traditional Open-Heart Surgery — Continuous Enhancements in Stent Deliverability, Flexibility, and Strut Thickness

    • 5.1.4 Robust Pipeline of Regulatory Approvals — Abbott Xience Sierra Flex (March 2025), Boston Scientific Synergy XD FDA Approval (February 2025), Medtronic Resolute Onyx CE Mark (January 2025)

    • 5.1.5 Increasing Adoption of Transradial PCI — Terumo Radifocus and Glidesheath Slender Enabling Radial Access Stent Procedures, Reducing Vascular Complications

    • 5.1.6 Growing Catheterization Laboratory Infrastructure — Expansion of Cath Labs in India, China, Brazil, and Southeast Asia Driving Procedural Volume Growth

    • 5.1.7 Technological Advancements — Polymer-Free Stents, Biodegradable Polymer DES, Bioadaptor Scaffolds, and AI-Assisted Robotic PCI Enabling Improved Long-Term Patient Outcomes

  • 5.2 Market Restraints

    • 5.2.1 High Cost of Angioplasty and Stent Procedures (USD 8,000–USD 30,000+ per PCI Episode) Limiting Access in Low- and Middle-Income Countries

    • 5.2.2 India NPPA Price Cap and China VBP Centralized Procurement Compressing Manufacturer Margins in High-Volume Emerging Markets

    • 5.2.3 Side Effects and Post-Procedural Complications — In-Stent Restenosis (ISR), Stent Thrombosis, and Prolonged DAPT Requirements Limiting Adoption in High Bleeding-Risk Patients

    • 5.2.4 Increasing Product Recalls Due to Safety Concerns Affecting Patient and Physician Trust (e.g., Early BVS Thrombosis Events Leading to Abbott ABSORB BVS Withdrawal)

    • 5.2.5 Availability of Alternative CAD Therapies — Drug-Coated Balloons (DCB), CABG Surgery, and Optimal Medical Therapy Competing with Coronary Stenting

  • 5.3 Market Opportunities

    • 5.3.1 Bioresorbable Scaffold Renaissance — DynamX Bioadaptor Demonstrated Statistically Significant Superiority Over Standard DES at 1-Year (TCT 2024: TLF 2.35% vs. 2.77%); Elixir Medical DynamX Entering Broad Clinical Rollout

    • 5.3.2 AI-Driven and Robotic PCI Systems — FDA-Approved Robotic-Assisted PCI System (June 2025) Enabling Improved Precision, Reduced Operator Fatigue, and Optimized Stent Placement

    • 5.3.3 Dual-Therapy and Smart Stents — OrbusNeich Genous/Combo EPC Capture Technology, Nanostructured Surface Coating, and Asymmetric Drug Layering Platforms

    • 5.3.4 Emerging Market Expansion — India (Biosensors International USD 200M Manufacturing Investment December 2024), Southeast Asia FDI Incentives, Brazil Expanding Cardiology Infrastructure

    • 5.3.5 Personalized Stent Design — 4D-Printed Patient-Specific Stent Architecture and AI-Guided Stent Selection Platforms for Complex Bifurcation and Small-Vessel Lesions

    • 5.3.6 Integration of Intracoronary Imaging — OCT and IVUS-Guided PCI Driving Higher-Quality Stent Implantation and Premium DES Adoption in Complex CAD Cases

    • 5.3.7 Medtronic–Terumo Strategic Partnership — Co-Development of Next-Generation Polymer-Free Stent Platform for Global Markets (January 2025)

  • 5.4 Market Challenges

    • 5.4.1 Overcoming Long-Term Safety Data Gaps for Bioresorbable Scaffolds — Limited 5–10 Year Real-World Clinical Evidence Relative to Proven Second-Generation DES

    • 5.4.2 Managing Physician Adoption Curve for Novel Stent Platforms — Training Requirements for Bioresorbable Scaffold Implantation Technique and Robotic PCI Integration

    • 5.4.3 Reimbursement Fragmentation — Emerging Value-Based Models and DRG System Inadequacies for Premium-Priced Absorb/Bioresorbable Stents (30–50% More Expensive Than Standard DES)

    • 5.4.4 Navigating Multi-Jurisdictional Regulatory Burden — Simultaneous FDA, EU MDR, NMPA, PMDA, and CDSCO Approval Timelines Extending Time-to-Market for Innovative Stent Platforms

6. Market Trends and Key Insights

  • 6.1 Drug-Eluting Stents (DES) Dominate by Revenue (76.51% Share in 2026 per FBI) — Second-Generation DES with Biodegradable Polymers and Ultra-Thin Struts Driving Premium Market Growth

  • 6.2 Bare-Metal Stents Retain Significant Volume Share (46.5% per CMI in 2026) — Cost Effectiveness, Shorter DAPT Requirements, and High-Bleeding-Risk Patient Preference Sustaining Demand

  • 6.3 Bioresorbable Scaffold Segment Recovering — DynamX Bioadaptor TCT 2024 Clinical Superiority Data and EMA Regulatory Streamlining (April 2025) Reigniting Clinical Adoption

  • 6.4 Self-Expandable Stents Dominant in Deployment (69.11% Share in 2026 per FBI) — Enhanced Trackability in Tortuous Vessels and Acute MI Applications Sustaining Leadership

  • 6.5 Cobalt-Chromium and Platinum-Chromium Alloys Commanding Premium Metallic Segment — Superior Radial Strength, Thinner Struts, and Enhanced Radiopacity vs. Stainless Steel

  • 6.6 Robotic-Assisted PCI Entering Clinical Mainstream — FDA Robotic PCI Approval (June 2025) Enabling Precision-Guided Stent Delivery and Positioning as Next Frontier in Interventional Cardiology

  • 6.7 Transradial Access Transforming PCI Practice — Terumo Glidesheath Slender and Radifocus Enabling Same-Day Discharge and Reduced Vascular Complications Across High-Volume Cath Labs

  • 6.8 India NPPA Price Reforms and China VBP Driving Margin Pressure — Market Participants Responding With Premium-Tier Platform Pivots and Local Manufacturing Partnerships

7. Impact Assessment

  • 7.1 Impact of COVID-19 on the Coronary Stents Market

    • 7.1.1 Pre-COVID Market Scenario

    • 7.1.2 Pandemic Impact: CMS Non-Urgent Classification of Elective PCI, Significant Procedure Volume Drop (2020), Revenue Decline Across Major Market Players, Cath Lab Redeployment for COVID-19 ICU Care

    • 7.1.3 Post-COVID Recovery: Pent-Up Procedure Backlog Recovery (2021–2023), Renewed Investment in Cath Lab Infrastructure, Accelerated Robotic and Imaging-Guided PCI Adoption

  • 7.2 Macroeconomic Indicators and Their Influence on Market Growth

    • 7.2.1 Global Inflationary Pressures Increasing Stent Procedure Costs While Driving India NPPA Price Revision (March 2025 ~2% Inflation Adjustment)

    • 7.2.2 Healthcare Budget Constraints in Europe and Emerging Markets Favoring Lower-Cost BMS and Domestically Manufactured DES Alternatives

    • 7.2.3 U.S. Medicare and Private Insurer DRG Reimbursement Adequacy for Premium Bioresorbable and Polymer-Free Stent Technologies

  • 7.3 Impact of FDA Robotic PCI Approval (June 2025), EU MDR Bioresorbable Stent Streamlining (April 2025), India NPPA NLEM Price Revisions, and China VBP Centralized Procurement on Market Dynamics

  • 7.4 Geopolitical Factors — U.S.-China Trade Tensions (Tariffs on Medical Device Components), India NLEM Price Regulation, Abbott India Market Strategy Pivot, and Southeast Asia Medical Device FDI Incentives

8. Strategic Framework Analysis

  • 8.1 Value Chain Analysis

    • 8.1.1 Raw Material Suppliers (Cobalt-Chromium Alloy, Platinum-Chromium, Stainless Steel, Medical-Grade Polymers, Sirolimus/Everolimus/Zotarolimus/Paclitaxel Active Drug Compounds)

    • 8.1.2 Stent Component Precision Manufacturers (Laser Cutting, Electropolishing, Surface Coating Specialists)

    • 8.1.3 Drug-Polymer Coating and Surface Functionalization Specialists (Biodegradable Polymer, PBMA/PVDF Durable Polymer, Polymer-Free Biolimus Coating)

    • 8.1.4 Stent Delivery System and Catheter Manufacturers (Balloon Catheter, Rapid Exchange System, Guiding Catheter)

    • 8.1.5 Coronary Imaging Technology Providers — IVUS (Philips, Boston Scientific Opticross HD), OCT (Abbott OPTIS Mobile, Gentuity MIMI), FFR/iFR (Abbott PressureWire X, Philips Verrata Plus)

    • 8.1.6 Sterilization, Validated Packaging, and Cold-Chain Logistics Partners

    • 8.1.7 End Users — Hospitals, Cath Labs, ASCs, Specialty Cardiology Clinics, Rehabilitation Centers

  • 8.2 Supply Chain Analysis and Risk Assessment (Cobalt-Chrome Alloy Sourcing, Drug API Purity, EO Sterilization Capacity, India/China Regulatory Price Controls on Supply Chain Economics)

  • 8.3 Porter's Five Forces Analysis

    • 8.3.1 Threat of New Entrants (Domestic Indian/Chinese Stent Manufacturers Aided by VBP/NLEM Procurement, AI-Native Robotic PCI Startups)

    • 8.3.2 Bargaining Power of Buyers (Hospital GPOs, National Health Systems Tender-Based Procurement, India NPPA-Controlled Pricing)

    • 8.3.3 Bargaining Power of Suppliers (Cobalt-Chrome Alloy Manufacturers, Sirolimus/Everolimus API Providers, Laser Cutting OEMs)

    • 8.3.4 Threat of Substitute Therapies (Drug-Coated Balloons — Agent DCB FDA Approval March 2024, CABG Surgery, Optimal Medical Therapy in Stable CAD)

    • 8.3.5 Competitive Rivalry Among Existing Players (Abbott 24.5% Share, Boston Scientific 21.0%, Medtronic 19.8%, Terumo 11.2%, MicroPort 7.5% per VMR)

  • 8.4 SWOT Analysis of the Overall Market

  • 8.5 Pricing Analysis and Trends by Product Type, Region, and Reimbursement System (BMS ₹10,692.69 India NPPA Cap; DES ₹38,933.14; Premium BRS 30–50% Above Standard DES; U.S. Medicare PCI DRG Bundled Rate Analysis)

  • 8.6 Technology Landscape and Innovation Matrix

    • 8.6.1 Second-Generation DES — Ultra-Thin Strut Cobalt-Chromium / Platinum-Chromium Platforms with Biodegradable Polymer Drug Elution (XIENCE Sierra Flex, Synergy XD, Resolute Onyx)

    • 8.6.2 Polymer-Free DES — BioFreedom Ultra Biolimus A9, Agent Paclitaxel Platform (ISR Application)

    • 8.6.3 Bioresorbable Vascular Scaffolds and Bioadaptors — DynamX Bioadaptor, Magmaris Magnesium BRS, Amaranth PLLA BRS

    • 8.6.4 Dual-Therapy Stents — OrbusNeich Genous/Combo EPC Capture + Sirolimus Elution

    • 8.6.5 AI-Guided Robotic PCI Delivery Systems — FDA-Approved Robotic PCI Platform (June 2025), Corindus CorPath GRX

    • 8.6.6 Intracoronary Imaging-Guided PCI — OCT, IVUS, and Co-Registration with Physiologic Assessment (FFR/iFR) for Optimized Stent Implantation

    • 8.6.7 4D Printing and Patient-Specific Stent Architecture — Emerging IP-Protected Platform for Personalized Complex Lesion PCI

  • 8.7 IP and Patent Landscape (Second-Generation DES Biodegradable Polymer, Bioresorbable Scaffold Material, Dual-Therapy EPC Capture, Nanostructured Surface Coating, AI-Guided Stent Placement Patent Clusters)

  • 8.8 M&A Activity, Strategic Partnerships, and Investment Landscape (2022–2026: Medtronic–Terumo Polymer-Free Platform January 2025, Biosensors International USD 200M Manufacturing Investment December 2024)

  • 8.9 Regulatory and Standards Landscape by Region (FDA 510(k)/PMA, EU MDR 2017/745 Class III, ISO 10993/14630, India NPPA/CDSCO, China NMPA/VBP, PMDA Japan, CE Mark Annex IX)

  • 8.10 Reimbursement Scenario — U.S. Medicare/Private Insurer DRG Coverage; EU (Germany/France Premium DES Reimbursement); India NLEM Price Cap (<2% Insurance Penetration); Japan PMDA Premium Tier for Bioresorbable Stents

  • 8.11 Prescribers' Preference Analysis — DES Preferred for Low-Bleeding-Risk Patients; BMS for High Bleeding Risk/Short DAPT; Cautious Bioresorbable Scaffold Adoption as DynamX Data Matures

  • 8.12 Drivers Impact Analysis on CAGR

9. Global Coronary Stents Market — By Stent Type

  • 9.1 Overview and Market Size, 2026–2033

  • 9.2 Drug-Eluting Stents (DES)

    • 9.2.1 Sirolimus-Eluting Stents (SES) — Abbott Xience Sierra Flex (March 2025 Launch), MicroPort Firehawk Targeted Abluminal Elution

    • 9.2.2 Everolimus-Eluting Stents (EES) — Abbott XIENCE Family (20M+ Patients Implanted, 120+ Clinical Trials)

    • 9.2.3 Zotarolimus-Eluting Stents (ZES) — Medtronic Resolute Onyx (CE Mark January 2025 Updated Polymer)

    • 9.2.4 Paclitaxel-Eluting Stents (PES) — TAXUS Platform (Mature Market; Largely Succeeded by New-Generation DES)

    • 9.2.5 Biolimus A9-Eluting Stents — Biosensors BioFreedom Ultra (PMDA/FDA Approved, Polymer-Free)

    • 9.2.6 Biodegradable Polymer DES — Boston Scientific Synergy XD Bioabsorbable Polymer DES (FDA Approval February 2025)

    • 9.2.7 Market Size, Share, and Forecast (76.51% Dominant Share in 2026 per FBI: Superior Restenosis Reduction, Broad Clinical Evidence, Established Reimbursement, Continuous Innovation Pipeline)

  • 9.3 Bare-Metal Stents (BMS)

    • 9.3.1 Stainless Steel BMS (Cost-Effective, Widely Available, Strong Radial Strength)

    • 9.3.2 Cobalt-Chromium BMS (Enhanced Radiopacity, Reduced Strut Thickness)

    • 9.3.3 Market Size, Share, and Forecast (46.5% Volume-Dominant Share per CMI in 2026: Affordability, No DAPT Extension Required, Essential for High Bleeding-Risk and Price-Capped Emerging Markets — India BMS NPPA Cap ₹10,692.69)

  • 9.4 Bioresorbable Stents / Vascular Scaffolds (BRS/BVS)

    • 9.4.1 Polymeric Bioresorbable Scaffolds — PLLA-Based (Amaranth Medical PLLA BRS, Biotronik DREAMS Predecessor)

    • 9.4.2 Metallic Bioresorbable Scaffolds — Magnesium-Based (Biotronik Magmaris — Enhanced Resorption Profile)

    • 9.4.3 Bioadaptor / Hemodynamic-Adaptive Scaffolds — Elixir Medical DynamX Bioadaptor (TCT 2024: TLF 2.35% vs. 2.77% Standard DES; Reuters October 2024)

    • 9.4.4 Market Size, Share, and Forecast (Fastest Growing Segment: DynamX Clinical Superiority Data, EMA Streamlined Regulation April 2025, Growing Surgeon Confidence in Next-Gen Resorbable Platforms)

  • 9.5 Covered Stents

    • 9.5.1 PTFE-Covered Stents for Coronary Perforation and Aneurysm Sealing

    • 9.5.2 Polyurethane-Covered Stents for Fistula Management and PCI Complications

    • 9.5.3 Market Size, Share, and Forecast (Niche Rescue Application Segment: High Unit Value, Low Volume)

  • 9.6 Others

    • 9.6.1 Dual-Therapy Stents (DTS) — OrbusNeich Genous/Combo EPC Capture + Sirolimus Elution

    • 9.6.2 Dedicated Bifurcation Stents (Tryton Side Branch Stent)

    • 9.6.3 Market Size, Share, and Forecast

10. Global Coronary Stents Market — By Material

  • 10.1 Overview and Market Size, 2026–2033

  • 10.2 Metallic Stents

    • 10.2.1 Stainless Steel (316L Medical Grade) — Cost-Effective BMS Workhorse; Standard Radial Strength; Widely Available in Emerging Markets

    • 10.2.2 Cobalt-Chromium Alloy (L-605, MP35N) — Second-Generation DES Standard; Superior Radial Strength at Reduced Strut Thickness (60–80 µm)

    • 10.2.3 Platinum-Chromium Alloy — Enhanced Radiopacity + High Radial Strength + Flexibility (Boston Scientific PROMUS Element / Synergy Platform)

    • 10.2.4 Silicon Carbide Coating — Enhanced Hemocompatibility and Reduced Platelet Activation (BIOTRONIK PRO-Kinetic Energy BMS)

    • 10.2.5 Titanium Nitride Oxide (TiNOx) Coating — Bioactive Surface for Rapid Endothelialization (Hexacath Titan2 BMS)

    • 10.2.6 Others (Nitinol, Tantalum, Niobium Alloys for Specialized Stent Applications)

    • 10.2.7 Market Size, Share, and Forecast (Dominant Material Segment: Widest Clinical Validation, Cost-Efficiency, and Regulatory Acceptance Across All Stent Types)

  • 10.3 Polymeric Stents

    • 10.3.1 Non-Degradable / Permanent Polymer Stents (Durable Polymer Coating on Metallic Scaffold — PBMA/PVDF Base Coating on First-Generation DES)

    • 10.3.2 Degradable / Temporary Polymer Stents (Biodegradable Polymer PLGA/PLLA Coating on Second-Generation DES — Synergy XD, Resolute Onyx Updated Polymer)

    • 10.3.3 Fully Polymeric Bioresorbable Scaffolds (PLLA or PDLLA Bioresorbable Backbone — Amaranth Medical PLLA BRS)

    • 10.3.4 Market Size, Share, and Forecast (Fastest Growing Material Type: Bioresorbable Scaffold Recovery Driven by DynamX TCT 2024 Data, EMA Regulation Streamlining, and PDLLA Scaffold Innovation)

11. Global Coronary Stents Market — By Deployment Mechanism

  • 11.1 Overview and Market Size, 2026–2033

  • 11.2 Self-Expandable Stents

    • 11.2.1 Nitinol Self-Expanding Coronary Scaffolds for Tortuous Vessels and Complex Anatomy

    • 11.2.2 Self-Expanding Stents in Acute MI — Precise Arterial Conformation Without Barotrauma

    • 11.2.3 Market Size, Share, and Forecast (69.11% Dominant Share in 2026 per FBI: Superior Trackability, Vessel Conformability, and Emerging Regional Manufacturer Availability)

  • 11.3 Balloon-Expandable Stents

    • 11.3.1 Rapid Exchange (Monorail) Balloon-Expandable DES (Industry Standard for Most PCI Procedures)

    • 11.3.2 Over-the-Wire (OTW) Balloon-Expandable Stents (Complex/CTO PCI Applications)

    • 11.3.3 Robotic-Assisted Balloon-Expandable Stent Delivery (FDA-Approved Robotic PCI Platform June 2025)

    • 11.3.4 Market Size, Share, and Forecast (Stable CAGR: Proven Clinical Safety Record, Dominant in Standard PCI; Robotic Integration Driving Premium Adoption)

12. Global Coronary Stents Market — By Application

  • 12.1 Overview and Market Size, 2026–2033

  • 12.2 Chronic Coronary Syndrome (CCS)

    • 12.2.1 Stable Angina Management — PCI + DES for Symptomatic Relief and Quality-of-Life Improvement

    • 12.2.2 Silent Ischemia and Multi-Vessel Disease — SYNTAX Trial-Guided PCI vs. CABG Decision-Making

    • 12.2.3 Complex CAD — Bifurcation, CTO, Small Vessel, and Long-Lesion PCI Applications

    • 12.2.4 Market Size, Share, and Forecast (89.21% Dominant Share in 2026 per FBI: Rising CAD Prevalence, Elective PCI Volume Recovery Post-COVID, Premium DES Adoption for Stable CAD)

  • 12.3 Acute Coronary Syndrome (ACS)

    • 12.3.1 ST-Elevation Myocardial Infarction (STEMI) — Primary PCI (pPCI) as Gold Standard (<90-Minute Door-to-Balloon Time)

    • 12.3.2 Non-ST-Elevation MI (NSTEMI) and Unstable Angina — Early Invasive PCI Strategy

    • 12.3.3 In-Stent Restenosis (ISR) Management — Agent Paclitaxel DCB (FDA Approved March 2024) as Non-Stent Option vs. DES-in-DES Restenting

    • 12.3.4 Market Size, Share, and Forecast (Significant CAGR: Rising ACS Event Rates in Younger Demographics, Lifestyle Disease Epidemic, STEMI System-of-Care Network Expansion in Emerging Markets)

13. Global Coronary Stents Market — By End User

  • 13.1 Overview and Market Size, 2026–2033

  • 13.2 Hospitals and Ambulatory Surgical Centers (ASCs)

    • 13.2.1 Tertiary Care Hospitals with Full-Service Cardiac Catheterization Laboratories

    • 13.2.2 Community Hospitals with Primary PCI STEMI Programs

    • 13.2.3 Ambulatory Surgical Centers with Cardiac Intervention Accreditation (CMS ASC Expansion for Low-Risk PCI)

    • 13.2.4 Market Size, Share, and Forecast (Dominant End User: 90%+ of All PCI Procedures Performed in Hospital/ASC Setting; Advanced Imaging Infrastructure, CSSD, and Emergency Cardiac Care Integration)

  • 13.3 Specialty Clinics

    • 13.3.1 Interventional Cardiology and Cardiovascular Disease Specialty Clinics

    • 13.3.2 Cardiac Rehabilitation and Post-PCI Follow-Up Clinics

    • 13.3.3 Market Size, Share, and Forecast (Moderate CAGR: Growing Specialist Cardiology Clinic Count in India, China, Brazil — Parallel to Expanding Cardiovascular Disease Awareness)

  • 13.4 Others

    • 13.4.1 Military and Defense Medical Facilities

    • 13.4.2 Research and Academic Medical Centers Conducting Coronary Stent Clinical Trials

    • 13.4.3 Market Size, Share, and Forecast

14. Global Coronary Stents Market — By Region

  • 14.1 Market Overview by Geography

  • 14.2 North America

    • 14.2.1 Market Size and Forecast (37.80% Dominant Share in 2026 per CMI; 33.55% per FBI — USD 2.35 Billion in 2025)

    • 14.2.2 United States (FDA Robotic PCI Approval June 2025; Agent DCB March 2024; Advanced Cath Lab Infrastructure; Medicare DRG PCI Bundled Reimbursement; CAD No. 1 Cause of Death)

    • 14.2.3 Canada (CIHR-Backed Stent Research, Provincial Healthcare PCI Program Expansion)

    • 14.2.4 Key Drivers, Trends, and Market Dynamics

  • 14.3 Europe

    • 14.3.1 Market Size and Forecast (EMA April 2025 Bioresorbable Stent Streamlining; Medtronic Resolute Onyx CE January 2025; EU MDR Class III Compliance Driving Portfolio Upgrades)

    • 14.3.2 Germany (~USD 0.64 Billion in 2026 per FBI — Largest European Market, State-Reimbursed Premium DES, Leading PCI Volume)

    • 14.3.3 United Kingdom (~USD 0.51 Billion in 2026 per FBI — NHS PCI Waiting List Reduction, NICE Technology Appraisal for DES)

    • 14.3.4 France (INAMI/CNAM DES Reimbursement Reform, Premium DES Access Through Public Hospital Tendering)

    • 14.3.5 Italy

    • 14.3.6 Spain

    • 14.3.7 Russia

    • 14.3.8 Rest of Europe

    • 14.3.9 Key Drivers, Trends, and Market Dynamics

  • 14.4 Asia Pacific

    • 14.4.1 Market Size and Forecast (Fastest Growing Region: Large CAD Patient Pool, Expanding Cath Lab Infrastructure, Rising PCI Procedure Volumes)

    • 14.4.2 Japan (~USD 0.25 Billion in 2026 per FBI — PMDA Premium Tier Bioresorbable Stent Reimbursement; BioFreedom Ultra PMDA Approval May 2022; Aging Population)

    • 14.4.3 China (~USD 0.39 Billion in 2026 per FBI — NMPA VBP Centralized Procurement; MicroPort Firehawk Domestic Leadership; Lepu Medical and Sahajanand Scale-Up)

    • 14.4.4 India (~USD 0.33 Billion in 2026 per FBI — NPPA Price Revision March 2025; Biosensors USD 200M Manufacturing Investment; Medical Tourism PCI Hub)

    • 14.4.5 South Korea (K-BIO Medical Technology Initiative, Samsung Medical Center PCI Innovation Programs)

    • 14.4.6 Australia and New Zealand

    • 14.4.7 ASEAN (Thailand, Malaysia, Vietnam — Growing Cath Lab FDI, Rising Cardiovascular Disease Burden)

    • 14.4.8 Rest of Asia Pacific

    • 14.4.9 Key Drivers, Trends, and Market Dynamics

  • 14.5 Latin America

    • 14.5.1 Market Size and Forecast (Rising PCI Volume, Growing Cardiology Infrastructure in Brazil and Mexico)

    • 14.5.2 Brazil (Private Insurance Expansion, São Paulo Cath Lab Network, Domestic Stent Distribution Partnerships)

    • 14.5.3 Mexico

    • 14.5.4 Argentina

    • 14.5.5 Rest of Latin America

    • 14.5.6 Key Drivers, Trends, and Market Dynamics

  • 14.6 Middle East and Africa

    • 14.6.1 Market Size and Forecast (PCI Infrastructure Investment in GCC; Expat and HNWI Population Access to Advanced Cardiac Care)

    • 14.6.2 GCC Countries (Saudi Arabia, UAE — Vision 2030 Healthcare Investment, Israeli PCI Innovation, Kuwait NIDCenter)

    • 14.6.3 Israel (Advanced PCI Technology Adoption, Elixir Medical DynamX Regional Distribution)

    • 14.6.4 South Africa

    • 14.6.5 North Africa and Central Africa

    • 14.6.6 Rest of Middle East and Africa

    • 14.6.7 Key Drivers, Trends, and Market Dynamics

15. Competitive Landscape

  • 15.1 Market Structure and Competitiveness Overview (Moderately Consolidated: Abbott 24.5%, Boston Scientific 21.0%, Medtronic 19.8%, Terumo 11.2%, MicroPort 7.5% per VMR; National Tenders in Asia Enabling Sahajanand, Meril Life Sciences, Lepu Medical to Erode Incumbent Price Segments)

  • 15.2 Market Share Analysis of Key Players

  • 15.3 Competitive Positioning Matrix

  • 15.4 Key Strategies Adopted by Market Leaders

    • 15.4.1 Next-Generation Product Innovation and FDA/CE Approvals — Abbott Xience Sierra Flex (March 2025), Boston Scientific Synergy XD FDA (February 2025), Medtronic Resolute Onyx CE (January 2025)

    • 15.4.2 Strategic Platform Partnership for Polymer-Free DES — Medtronic–Terumo Co-Development Agreement (January 2025) Targeting Global Markets

    • 15.4.3 Robotic and AI-Guided PCI Integration — FDA Robotic PCI System Approval (June 2025) Enabling Precision-Guided Stent Delivery as Premium Market Differentiator

    • 15.4.4 Emerging Market Manufacturing Investment — Biosensors International USD 200M Capacity Expansion in India and China (December 2024)

    • 15.4.5 Intracoronary Imaging and Physiologic Assessment Portfolio Integration — Abbott OPTIS/PressureWire X, Philips IVUS/iFR as Premium PCI Guidance Ecosystem Bundled with DES

  • 15.5 Recent Developments and Industry News (2024–2026)

  • 15.6 Pipeline Analysis — Next-Generation Bioresorbable Scaffolds, Polymer-Free DES, Smart Stent Platforms, and 4D-Printed Personalized Stent Architectures Under Clinical Development

16. Company Profiles
(The final report includes a complete list of companies)

  • 16.1 Abbott Laboratories

    • 16.1.1 Company Overview

    • 16.1.2 Financial Performance

    • 16.1.3 Product Portfolio

    • 16.1.4 Strategic Initiatives

    • 16.1.5 SWOT Analysis

  • 16.2 Boston Scientific Corporation

  • 16.3 Medtronic plc

  • 16.4 Terumo Corporation

  • 16.5 BIOTRONIK SE & Co. KG

  • 16.6 B. Braun SE (Aesculap)

  • 16.7 MicroPort Scientific Corporation

  • 16.8 Biosensors International Group Ltd.

  • 16.9 Meril Life Sciences Pvt. Ltd.

  • 16.10 OrbusNeich Medical Technologies

  • 16.11 Elixir Medical Corporation

  • 16.12 Sahajanand Medical Technologies (SMT)

  • 16.13 Cook Medical Technologies LLC

  • 16.14 Translumina Therapeutics LLP

  • 16.15 Lepu Medical Technology (Beijing) Co., Ltd.

17. Appendix

  • 17.1 Abbreviations and Acronyms

  • 17.2 List of Tables

  • 17.3 List of Figures

  • 17.4 About the Publisher

  • 17.5 Research Process and Data Sources

18. Disclaimer

Enhance your decision-making capabilities with a 5 Reports-in-1
Bundle deal for - more than 40% off!

Our professional analysts will provide you with immediate assistance.